Switch theme
Sign up to access all valuation multiples
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
2004
34
LTM Revenue $6.5M
LTM EBITDA $2.1M
$16.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arterra Bioscience has a last 12-month revenue (LTM) of $6.5M and a last 12-month EBITDA of $2.1M.
In the most recent fiscal year, Arterra Bioscience achieved revenue of $4.9M and an EBITDA of $2.4M.
Arterra Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arterra Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | XXX | $4.9M | XXX | XXX | XXX |
| Gross Profit | $4.5M | XXX | $4.3M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $2.1M | XXX | $2.4M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 49% | XXX | XXX | XXX |
| EBIT | $1.7M | XXX | $1.7M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 35% | XXX | XXX | XXX |
| Net Profit | $1.6M | XXX | $1.6M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 32% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Arterra Bioscience's stock price is EUR 3 (or $3).
Arterra Bioscience has current market cap of EUR 16.7M (or $19.6M), and EV of EUR 13.7M (or $16.1M).
See Arterra Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.1M | $19.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Arterra Bioscience has market cap of $19.6M and EV of $16.1M.
Arterra Bioscience's trades at 3.3x EV/Revenue multiple, and 6.7x EV/EBITDA.
Equity research analysts estimate Arterra Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arterra Bioscience has a P/E ratio of 12.2x.
See valuation multiples for Arterra Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.6M | XXX | $19.6M | XXX | XXX | XXX |
| EV (current) | $16.1M | XXX | $16.1M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 9.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.2x | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | 8.9x | XXX | 34.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArterra Bioscience's last 12 month revenue growth is 11%
Arterra Bioscience's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Arterra Bioscience's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arterra Bioscience's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arterra Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 67% | XXX | 60% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arterra Bioscience acquired XXX companies to date.
Last acquisition by Arterra Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Arterra Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arterra Bioscience founded? | Arterra Bioscience was founded in 2004. |
| Where is Arterra Bioscience headquartered? | Arterra Bioscience is headquartered in Italy. |
| How many employees does Arterra Bioscience have? | As of today, Arterra Bioscience has 34 employees. |
| Is Arterra Bioscience publicy listed? | Yes, Arterra Bioscience is a public company listed on MIL. |
| What is the stock symbol of Arterra Bioscience? | Arterra Bioscience trades under ARBS ticker. |
| When did Arterra Bioscience go public? | Arterra Bioscience went public in 2019. |
| Who are competitors of Arterra Bioscience? | Similar companies to Arterra Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arterra Bioscience? | Arterra Bioscience's current market cap is $19.6M |
| What is the current revenue of Arterra Bioscience? | Arterra Bioscience's last 12 months revenue is $6.5M. |
| What is the current revenue growth of Arterra Bioscience? | Arterra Bioscience revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Arterra Bioscience? | Current revenue multiple of Arterra Bioscience is 2.5x. |
| Is Arterra Bioscience profitable? | Yes, Arterra Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arterra Bioscience? | Arterra Bioscience's last 12 months EBITDA is $2.1M. |
| What is Arterra Bioscience's EBITDA margin? | Arterra Bioscience's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Arterra Bioscience? | Current EBITDA multiple of Arterra Bioscience is 7.5x. |
| What is the current FCF of Arterra Bioscience? | Arterra Bioscience's last 12 months FCF is $1.8M. |
| What is Arterra Bioscience's FCF margin? | Arterra Bioscience's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of Arterra Bioscience? | Current FCF multiple of Arterra Bioscience is 8.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
